News stories about Ampliphi Biosciences Corp (NYSE:APHB) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Ampliphi Biosciences Corp earned a news sentiment score of 0.05 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.8889193233466 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Ampliphi Biosciences Corp (NYSE:APHB) traded up 2.7253% during trading on Monday, reaching $0.9348. The company had a trading volume of 68,036 shares. Ampliphi Biosciences Corp has a 52 week low of $0.67 and a 52 week high of $16.90. The firm has a 50-day moving average of $0.85 and a 200 day moving average of $1.08. The firm’s market capitalization is $8.18 million.

TRADEMARK VIOLATION WARNING: This piece was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at

Ampliphi Biosciences Corp Company Profile

AmpliPhi Biosciences Corporation is a biotechnology company. The Company is focused on the discovery, development and commercialization of phage therapeutics. The Company is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

Insider Buying and Selling by Quarter for Ampliphi Biosciences Corp (NYSE:APHB)

Receive News & Stock Ratings for Ampliphi Biosciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences Corp and related stocks with our FREE daily email newsletter.